Kalmar Investments’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$5.24M Sell
72,853
-307,860
-81% -$21.3M 1.18% 41
2016
Q4
$23.6M Sell
380,713
-48,376
-11% -$2.96M 1.21% 21
2016
Q3
$27.8M Sell
429,089
-30,775
-7% -$2.05M 1.27% 21
2016
Q2
$29.1M Sell
459,864
-25,630
-5% -$1.51M 1.28% 25
2016
Q1
$28.1M Sell
485,494
-489,982
-50% -$27.7M 1.15% 32
2015
Q4
$52.4M Sell
975,476
-53,521
-5% -$3.02M 1.28% 16
2015
Q3
$52.4M Sell
1,028,997
-57,525
-5% -$3.1M 1.23% 18
2015
Q2
$61.2M Sell
1,086,522
-19,289
-2% -$1.22M 1.16% 24
2015
Q1
$79.4M Sell
1,105,811
-52,720
-5% -$3.42M 1.48% 10
2014
Q4
$64.9M Sell
1,158,531
-18,593
-2% -$971K 1.21% 20
2014
Q3
$58M Sell
1,177,124
-10,675
-0.9% -$544K 1.1% 28
2014
Q2
$60.1M Buy
1,187,799
+4,640
+0.4% +$230K 1.03% 30
2014
Q1
$52.9M Sell
1,183,159
-189,827
-14% -$8.53M 0.89% 41
2013
Q4
$64.6M Buy
1,372,986
+2,495
+0.2% +$126K 1.08% 28
2013
Q3
$72.4M Sell
1,370,491
-7,625
-0.6% -$370K 1.28% 20
2013
Q2
$62.2M Buy
+1,378,116
New +$65.4M 1.22% 20

Other funds holding RMD

Kalmar Investments's RMD Position: Q1 2017 in Review

Kalmar Investments reduced its ResMed (RMD) stake by 81% in Q1 2017, selling an estimated $21.3M and leaving 72,853 shares worth $5.24M. The position accounts for 1.18% of the portfolio, ranked #41.

Kalmar Investments first reported a position in RMD in Q2 2013 and has held it in 16 quarters since. The position peaked at $79.4M in Q1 2015. 375 funds tracked by Wall St. Rank hold RMD as of Q1 2017.

  • Kalmar Investments held 72,853 shares of ResMed worth $5.24M as of Q1 2017.
  • Kalmar Investments sold 307,860 ResMed shares in Q1 2017, an estimated $21.3M.
  • ResMed made up 1.18% of Kalmar Investments's portfolio in Q1 2017, its #41 holding.
  • Kalmar Investments first reported a position in ResMed in Q2 2013 and has held it in 16 quarters since.
  • Kalmar Investments's ResMed position peaked at $79.4M in Q1 2015.
  • 375 funds tracked by Wall St. Rank held ResMed as of Q1 2017.

Based on Kalmar Investments's 13F filing for Q1 2017, filed 26 Apr 2017.